


FANTOM II: Excellent Clinical Performance through 2 Years

Fantom[®]
Tyrocore Bioresorbable Scaffold

2-Year Target Lesion Failure (TLF*)



Low MACE Rate Sustained at 2 Years¹

| | 12 Months, (n=240) | 24 Months, (n=240) |
|-----------------------|--------------------|--------------------|
| MACE | 4.2% (10) | 5.0% (12) |
| Cardiac Death | 0.8% (2) | 0.8% (2) |
| All MI | 1.3% (3) | 1.7% (4) |
| Clinically Driven TLR | 2.5% (6) | 2.9% (7) |

FANTOM II Clinical Trial

- ✓ 240 patients enrolled
- ✓ 153 matched OCT image pairs
- ✓ 28 centers
- ✓ 8 countries

* TLF = cardiac death + target vessel MI + target lesion revascularization. The FANTOM II primary endpoint was Major Adverse Cardiac Events (MACE) = cardiac death + all MI + target lesion revascularization.

Low ST Rates during Scaffold Degradation through 2 Years¹


| Def/Prob Scaffold Thrombosis, (n=240) | |
|---------------------------------------|-----------------------|
| Acute (0–1 day) | 0.0% (0) |
| Sub-acute (2–30 days) | 0.4% (1) ^a |
| Late (31–365 days) | 0.0% (0) |
| Very Late (>365 days) | 0.4% (1) ^b |

a) Target lesion was not fully covered with scaffold. Significant untreated stenosis was present at index procedure.


b) Distal segment of scaffold was in a 2.0mm vessel and the scaffold had significant malaposition that was not corrected.

Sustained vessel patency and strut coverage⁶

FANTOM II 24-month OCT analysis: matched OCT images at baseline, 6 months, and 24 months, n=25



FANTOM II case sample: matched OCT images at baseline, 6 months, and 24 months



Reference List

1. Data on file at REVA Medical. MACE rates presented: Abizaid, A. New 24-month data from the FANTOM II clinical trial. EuroPCR 2018.
2. Ellis S, Kereiakes, D. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent: ABSORB III. ACC 2017.
3. Haude M, et al. Short and midterm safety, clinical performance and multimodality imaging results of the drug-eluting absorbable metal scaffold: Combined data of the BIOSOLVE-II and BIOSOLVE-III trials. EuroPCR 2017.
4. Stone G, et al. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents 2-Year Follow-Up From the SPIRIT IV Trial. JACC 2011;58(1):19-25.
5. Mauri L. 2-year clinical outcomes from the pivotal RESOLUTE US study. Presented ACC 2012.
6. Holm, NR. REVA FANTOM II performance and healing patterns by OCT two-year serial follow up. EuroPCR 2018.